Autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05251870 (ClinicalTrials.gov) | August 17, 2021 | 21/12/2021 | Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis | Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis: the TOLERANT Trial | Rheumatoid Arthritis | Drug: autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 | UMC Utrecht | Radboud University Medical Center;Utrecht University;Trajectum Pharma B.V.;Dutch Arthritis Association;ZonMw: The Netherlands Organisation for Health Research and Development;Health Holland | Recruiting | 18 Years | N/A | All | 18 | Phase 1/Phase 2 | Netherlands |